Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19

Show other versions (1)

The SARS-CoV-2 3CL protease is a critical drug target for small molecule COVID-19 therapy, given its likely druggability and essentiality in the viral maturation and replication cycle. Based on the conservation of 3CL protease substrate binding pockets across coronaviruses and using screening, we id...

Full description

Bibliographic Details
Main Authors: Bartolo-Cruz, M. (Author), Bednarova, E. (Author), Chavez, A. (Author), Daniels, J.D (Author), Farina, M. (Author), Forouhar, F. (Author), Fowler, B. (Author), Ho, D.D (Author), Hong, S.J (Author), Huang, Y. (Author), Hurst, B.L (Author), Iketani, S. (Author), Jurtschenko, C. (Author), Karan, C. (Author), Khanizeman, N. (Author), Lauber, M.A (Author), Lee, S. (Author), Li, W. (Author), Liu, H. (Author), McDonald, T. (Author), Mohri, H. (Author), Nair, M.S (Author), Quinn, C. (Author), Rajbhandari, P. (Author), Resnick, S.J (Author), Rovis, T. (Author), Shion, H. (Author), Stockwell, B.R (Author), Stokes, M.E (Author), Tay, N.E.S (Author), Xia, X. (Author), Zask, A. (Author)
Format: Article
Language:English
Published: Nature Research 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items